High-cost cell and gene therapies are changing the severity profile of health insurance claims. For organisations operating in stop-loss and captive environments, the issue is not only the size of potential claims, but whether pricing, retention strategy, and structure are keeping pace with the level of exposure these therapies can introduce.
Why This Matters Now
Cell and gene therapies represent important clinical progress, but they also introduce a different order of financial exposure into the health insurance system. Industry and actuarial sources note that these treatments can carry multi-million-dollar price tags, and that self-insured employers with stop-loss coverage can still remain exposed to portions of the cost depending on how coverage and payment arrangements are structured.
The Financial Reality of Emerging Therapies
For organisations involved in stop-loss and health captives, this changes the nature of actuarial planning. The issue is no longer simply whether catastrophic claims are possible. It is whether current assumptions, structures, and retention decisions are well matched to a severity environment that is becoming harder to treat as exceptional. Milliman’s analysis specifically points to the need to assess how gene and cell therapy costs are shared between self-insured employers, stop-loss carriers, and manufacturers, while Society of Actuaries material also highlights how risk is distributed across employers, stop-loss carriers, and reinsurers.
Where Exposure Begins to Surface
This pressure can show up in several places. Pricing may need to reflect exposures that are infrequent but severe. Captive structures may need to be reviewed to understand whether retained risk still aligns with the original intent and resilience of the arrangement. Product sustainability may also need closer attention when the financial impact of a single claim can be concentrated rather than gradual. These are the kinds of issues actuarial and stop-loss sources continue to raise in relation to high-cost therapies and their downstream effect on underwriting, pricing, and risk transfer.
“We called Imagine Clany Eco when another company cancelled on us last minute for our move-out cleaning. Clany Eco was able to book us and make it out in 2 hours and did an amazing job. We even got our deposit back.”
What This Means for Pricing, Retention, and Structure
As emerging therapies become a more material part of the claims landscape, organisations need greater clarity on whether existing pricing logic, retention decisions, and structural assumptions remain appropriate. That includes understanding where exposure sits, how much volatility can realistically be absorbed, and whether risk-sharing arrangements are still fit for purpose in a higher-severity environment.
The Value of Acting Earlier
The value of early actuarial assessment is clarity. Acting earlier helps organisations better understand how risk is distributed, where assumptions may need strengthening, and whether pricing and structure remain defensible as the market evolves. In an area where claim severity can be significant and concentrated, stronger decisions usually come from addressing the issue before the pressure is fully visible in experience data.